Department of Pathology, Massachusetts General Hospital, Boston, MA, USA.
Harvard Medical School, Massachusetts General Hospital, Boston, MA, USA.
Histopathology. 2021 Jun;78(7):951-962. doi: 10.1111/his.14309. Epub 2021 Apr 19.
Perinephric fat invasion (PFI) is a key component of renal cell carcinoma (RCC) staging, but there are limited data pertaining to biopsy tract seeding (BTS) resulting in perirenal tissue involvement [BTS with perinephric fat invasion (BTS-P)].The aim is to correlate clinical outcomes with pathologic stage to determine whether the presence of BTS-P should be considered a criterion to stage RCC as part of the pT3a category in the absence of any other upstaging variables.
We identified 304 renal biopsies from patients with subsequent nephrectomies for RCC; 33 of the tumours contained PFI. Each case was reviewed to determine the presence of BTS-P and other forms of invasion [e.g. non-BTS-P PFI, sinus fat invasion (SFI), and/or renal vein invasion (RVI)], and these findings were compared with survival outcomes. Ten (30%) of 33 tumours with PFI showed BTS-P as the only finding, and were otherwise pT1 tumours; six (60%) patients were alive without disease (AWOD) (mean, 77.5 months), three were lost to follow-up (LTF), and one died of other disease (DOOD). Two patients showed true PFI plus BTS-P; one was LTF and one is AWOD at 107 months. Ten (43%) of 23 patients with tumours with true invasion (PFI ± SFI and/or RVI) are AWOD (mean, 97.7 months), eight (35%) died of disease (DOD), four were LTF, and one DOOD. Kaplan-Meier survival curves showed that the cancer-specific survival was significantly worse in patients with true invasion (P = 0.044) than in those with BTS-P as the sole finding.
Patients with tumours showing BTS-P only appear to have better outcomes than those with other non-PFI invasion, suggesting that this finding should not be upstaged to pT3a. Additional studies are needed to corroborate the significance of our observations.
肾周脂肪浸润(PFI)是肾细胞癌(RCC)分期的关键组成部分,但有关活检通道播种(BTS)导致肾周组织受累[BTS 伴肾周脂肪浸润(BTS-P)]的数据有限。目的是将临床结果与病理分期相关联,以确定是否存在 BTS-P 应被视为将 RCC 分期为 pT3a 类别的标准,而不考虑任何其他升级变量。
我们从随后因 RCC 而行肾切除术的患者中确定了 304 例肾活检;其中 33 例肿瘤存在 PFI。每个病例均进行了复查,以确定是否存在 BTS-P 和其他形式的浸润[例如非 BTS-P PFI、窦脂肪浸润(SFI)和/或肾静脉浸润(RVI)],并将这些发现与生存结果进行了比较。33 例 PFI 肿瘤中有 10 例(30%)仅显示 BTS-P,且为 pT1 肿瘤;6 例(60%)患者无病生存(AWOD)(平均,77.5 个月),3 例失访(LTF),1 例死于其他疾病(DOOD)。2 例显示真正的 PFI 加 BTS-P;1 例 LTF,1 例 107 个月时 AWOD。23 例具有真正浸润(PFI ± SFI 和/或 RVI)的患者中有 10 例(43%)AWOD(平均,97.7 个月),8 例(35%)死于疾病(DOD),4 例 LTF,1 例 DOOD。Kaplan-Meier 生存曲线显示,具有真正浸润的患者的癌症特异性生存率明显低于仅显示 BTS-P 的患者(P=0.044)。
仅显示 BTS-P 的肿瘤患者的预后似乎优于具有其他非 PFI 浸润的患者,这表明不应将这些发现升级为 pT3a。需要进一步的研究来证实我们观察结果的意义。